Applications of Cellular Radiolabeling in Transfusion Medicine

Rossi's Principles of Transfusion Medicine: Fourth Edition

Volumn , Issue , 2009, Pages 298-317

  Dumont, Larry J ^a,b   AuBuchon, James P ^c   Davey, Richard J ^d,e  

^a Cell Labeling Laboratory   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c PUGET SOUND BLOOD CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991503910     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303513.ch21     Document Type: Chapter

References (170)

1. Alavi JB, Alavi A, Staum MM. Evaluation of infection in neutropenic patients with indium-111-labeled donor granulocytes. Clin Nucl Med 1980;5:397-400.
2. Anstall HB, Coleman RE. Donor leukocyte imaging in granulocytopenic patients with suspected abscesses. J Nucl Med 1982;23:319-21.
3. Loken MK, Clay ME, Carpenter RT, et al. Clinical use of indium- 111-labeled blood products. Clin Nucl Med 1985;10:902-11.
4. Weiblen BJ, Forstrom L, McCullough J. Studies of the kinetics of indium-111-labeled granulocytes. J Lab Clin Med 1979;94:246-57.
5. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-41.
6. Kelly MJ, Cowie AR, Antonino A, et al. An assessment of factors which influence the effectiveness of the modified in vivo technetium- 99 m-erythrocyte labeling technique in clinical use. J Nucl Med 1992;33:2222-5.
7. 51chromium posttransfusion recovery of red cells stored in saline, adenine, glucose, and mannitol for 42 days. Vox Sang 1989;57:37-42.
8. Heaton WA. Evaluation of posttransfusion recovery and survival of transfused red cells. Transfus Med Rev 1992;6:153-69.
9. Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962;51:224-32.
10. Hurley PJ. Red cell and plasma volumes in normal adults. J Nucl Med 1975;16:45-52.
11. Valeri CR. Measurement of viable ADSOL-preserved human red cells. N Engl J Med 1985;312:377-8.
12. 51-tagged erythrocytes in relation to blood volume determination. Blood 1958;13:128-45.
13. Siegel JA, Thomas SR, Stubbs JB, et al. Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S-61S.
14. Pickard C, AuBuchon JP, Tosteson ANA, Holme S. Influence of gender and collection order on radiolabeled red blood cell recovery (abstract). Transfusion 1995;35(Suppl):6S.
15. Whitley PH, Sawyer S, Averett N, et al. An initial comparison of in vivo single vs. double label 24 hour % recovery (abstract). Transfusion 2006;46(Suppl):74A.
16. International Committee for Standardization in Haematology. Recommended method for radioisotope red-cell survival studies. Br J Haematol 1980;45:659-66.
17. 51Cr survival curves. Br J Haematol 1971;20:527-34.
18. Klein HG, Anstee DJ. Mollison's blood transfusion in clinical medicine. 11th ed. Oxford: Blackwell, 2005:352-61.
19. International Committee for Standardization in Haematology. Recommended methods for radioisotope red-cell survival studies. Br J Haematol 1971;21:41-55.
20. International Committee for Standardization in Haematology. Recommended methods for measurement of red-cell and plasma volume. J Nucl Med 1980;21:793-800.
21. 51Cr. In: Bell CA, ed. A seminar on immunemediated cell destruction. Washington, DC: AABB, 1981:45-69.
22. International Committee for Standardization in Hematology. Recommended method for indium-11 platelet survival studies. J Nucl Med 1988;29:564-6.
23. Taylor HL, Whitley P, Heaton A. A historical perspective on platelet radiolabeling techniques. Transfusion 2006;46(Suppl):53S-58S.
24. Lötter MG, Rabe WLR, van Zyl LM, et al. A computer program in compiled BASIC for the IBM personal computer to calculate the mean platelet survival time with the multiple-hit and weighted mean methods. Comput Biol Med 1988;18:305-15.
25. AuBuchon JP, Herschel L, Roger J, et al. Comparison of computerized formulae for determination of platelet recovery and survival. Transfusion 2005;45:1237-8.
26. Gray SJ, Sterling K. The tagging of red cells and plasma proteins with radioactive chromium. J Clin Invest 1950;29:1604-13.
27. Fisher J, Wolfe R, Leon A. Technetium-99 m as a label for erythrocytes. J Nucl Med 1967;8:229-32.
28. McAfee JG, Thakur ML. Survey of radioactive agents for in vitro labeling of phagocytic leukocytes: I. Soluble agents. J Nucl Med 1976;17:480-7.
29. 51Cr as a label for red cells. Br J Haematol 1955;1:62-74.
30. 51Cr red cell survival studies. Br J Haematol 1974;26:179-84.
31. Moroff G, Sohmer PR, Button LN. Proposed standardization of methods for determining the 24hour survival of stored red cells. Transfusion 1984;24:109-14.
32. Al Sioufi H, Button L, Propper R, et al. A novel non-radioactive method for red cell survival in humans (abstract). Transfusion 1984;24(Suppl):415.
33. Baldini M, Costea N, Dameshek W. The viability of stored human platelets. Blood 1960;16:1669-92.
34. Snyder EL, Moroff G, Simon T, Heaton A. Recommended methods for conducting radiolabeled platelet survival studies. Transfusion 1986;26:37-42.
35. 51Cr allows accurate evaluation of platelet viability of stored platelet concentrates. Br J Hematol 1993;84:717-23.
36. 99mTc for determination of red cell volume. Br J Haematol 1978;38:141-8.
37. Holt JT, Spitalnik SL, McMican AE, et al. A technetium-99 m red cell survival technique for in vivo compatibility testing. Transfusion 1983;23:148-51.
38. AuBuchon JP, Brightman A. Use of indium-111 as a red cell label. Transfusion 1989;29:143-7.
39. Mountford PJ, Allsopp MJ, Hall FM, et al. Leucocyte and contaminant cell-bound activities resulting from the labeling of leucocytes with indium-111 oxine. Eur J Nucl Med 1985;10:304-7.
40. Callender STE, Powell EO, Witts LJ. The life-span of the red cell in man. J Pathol Bacteriol 1945;57:129-39.
41. Berlin NI. Determination of red cell life span. JAMA 1964;188:375-8.
42. Propper RD, Button LN, Nathan DG. New approaches to the transfusion management of thalassemia. Blood 1980;55:55-60.
43. Corash L, Klein H, Deisseroth A, et al. Selective isolation of young erythrocytes for transfusion support of thalassemia major patients. Blood 1981;57:599-606.
44. Simon TL, Sohmer P, Nelson EJ. Extended survival of neocytes produced in a new system. Transfusion 1989;29:221-5.
45. Cohen AR, Schmidt JM, Martin MB, et al. Clinical trial of young red cell transfusions. J Pediatr 1984;104:865-98.
46. Ness PM, Shirey RS, Thoman SK, Buck SA. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: Incidence, long-term serologic findings and clinical significance. Transfusion 1990;30:688-93.
47. Vamvakas EC, Pineda AA, Reisner R, et al. The differentiation of delayed hemolytic and delayed serologic transfusion reactions: Incidence and predictors of hemolysis. Transfusion 1995;35:26-32.
48. Davey RJ. Mechanisms of premature red cell destruction. In: Judd WJ, Barnes A, eds. Clinical and serological aspects of transfusion reactions. Arlington, VA: AABB, 1982:1-35.
49. Mollison PL. Survival curves of incompatible red cells. Transfusion 1986;26:43-50.
50. Garratty G. Factors affecting the pathogenicity of red cell allo- and autoantibodies. In: Nance ST, ed: Immune destruction of red blood cells. Arlington, VA: AABB, 1987:114-22.
51. Garratty G. The significance of complement in immunohematology. CRC Crit Rev Clin Lab Sci 1984;20:25-6.
52. Freedman J. The significance of complement on the red cell membrane. Transfus Med Rev 1987;1:58-70.
53. Davenport RD, Burdick M, Moore SA, Kunkel SL. Cytokine production in IgG-mediated red cell incompatibility. Transfusion 1993;33:19-24.
54. Davenport RD, Kunkel SL. Cytokine roles in hemolytic and nonhemolytic transfusion reactions. Transfus Med Rev 1994;8:157-68.
55. Engelfriet CP, Overbeeke MAM, Dooren MC, et al. Bioassays to determine the clinical significance of red cell antibodies based on Fc receptor-induced destruction of red cells sensitized by IgG. Transfusion 1994:34:617-26.
56. Jaffe CJ, Atkinson JP, Frank MM. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J Clin Invest 1976;58:942-9.
57. Horsewood P, Kelton JG. Macrophage-mediated cell destruction. In: Garraty G, ed. Immunobiology of transfusion medicine. New York: Marcel Dekker, 1994:435-64.
58. Lachmann PJ, Pangburn MK, Oldroyd RG. Breakdown of C3 after complement activation. J Exp Med 1982;156:205-76.
59. Atkinson JP, Frank MM. Studies on the in vivo effects of antibody: Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J Clin Invest 1974;54:339-48.
60. Gaither TA, Vargas I, Inada S, Frank MM. The complement fragment C3d facilitates phagocytosis by monocytes. Immunology 1987;62:405-11.
61. Ehlenberger AG, Nussenzweig V. The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med 1977;145:357-71.
62. Aas KA, Gardner FH. Survival of blood platelets labeled with chromium-51. J Clin Invest 1958;37:1257-68.
63. Thakur ML, Walch MJ, Malek HL, Gottschalk A. Indium-111-labeled human platelets: Improved method, efficacy, and evaluation. J Nucl Med 1981;22:381-5.
64. Holme S. Storage and quality assessment of platelets. Vox Sang 1998;74(suppl 2):207-16.
65. AuBuchon JP, Taylor H, Holme S, Nelson E. In vitro and in vivo evaluation of the leukoreduced platelets stored for 7 days in CLX(r) containers. Transfusion 2005;45:1356-61.
66. 111In-acetyl acetone for the labeling of cells: In vivo and vitro biological testing. Int J Appl Radiat Isot 1981;32:651-6.
67. Dewanjee MK, Rao SA, Rosemark JA, et al. Indium-111 tropolone, a new tracer for platelet labeling. Radiology 1982;145:149-53.
68. Thakur ML, McKenney SL, Park CH. Simplified and efficient labeling of human platelets in plasma using indium-111-2- mercaptopyridine-N-oxide: Preparation and evaluation. J Nucl Med 1985;26:510-17.
69. Murphy S. Radiolabeling of PLTs to assess viability: A proposal for a standard. Transfusion 2004:44:131-3.
70. AuBuchon JP, Dumont L, Murphy S, et al. Comparison of computerized formulae for determination of platelet recovery and survival. Transfusion 2005;45:1237-8.
71. Paulus JM, Aster RH. Platelet kinetics: Production distribution, lifespan, and fate of platelets. In: Williams W, Beutler E, Erslev A, Lichtman M, eds: Hematology. 3rd ed. New York: McGraw-Hill, 1983:1185-96.
72. Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1969;48:963-74.
73. Heyns A du P, Lotter MG, Badenhorst PN, et al. Kinetics, distribution and sites of destruction of indium-111-labeled human platelets. Br J Haematol 1980;44:269-80.
74. Klonizakis I, Peters AM, Fitzpatrick ML, et al. Radionuclide distribution following injection of In-111-labeled platelets. Br J Haematol 1980;46:595-602.
75. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement. Blood 1985;66:1105-9.
76. Read EJ. Leukocyte radiolabeling. In: Davey RJ, Wallace ME, eds. Diagnostic and investigational uses of radiolabeled blood elements. Arlington, VA: AABB, 1987:93-114.
77. McAfee JG, Subramanian G, Gagne G. Technique of leukocyte harvesting and labeling: Problems and perspectives. Semin Nucl Med 1984;12:83-106.
78. Athens JW, Haab OP, Raab SO, et al. Leukokinetic studies: IV. The total blood, circulating and marginal granulocyte pools and granulocyte turnover rate in normal subjects. J Clin Invest 1961;40:989-95.
79. Alexanian R, Donahue DM. Neutrophilic granulocyte kinetics in normal man. J Appl Physiol 1965;20:803-8.
80. Peters AM. Saverymuttu SH, Bell RN. Quantification of the distribution of the margination granulocyte pool in man. Scand J Haematol 1985;34:111-20.
81. 111indium-labelled granulocytes: Relationship to labelling techniques. Scand J Haematol 1983;30:151-60.
82. Dutcher JP, Fox JJ, Riggs C, et al. Pulmonary retention of indium- 111-labeled granulocytes in alloimmunized patients (abstract). Blood 1982;58:177a.
83. 111In granulocytes. Blood 1986;67:522-8.
84. Dutcher JP, Schiffer CA, Johnston CS, et al. Alloimmunization prevents the migration of transfused indium-111-labeled granulocytes to sites of infection. Blood 1983;62:354-60.
85. Read EJ, Keenan AM, Carter CS, et al. In vivo traffic of indium-111- oxine labeled human lymphocytes collected by automated apheresis. J Nucl Med 1990;31:999-1006.
86. Ford WL, Gowans JL. The traffic of lymphocytes. Semin Hematol 1969;6:67-83.
87. Lee TH, Paglieroni T, Ohto H, et al. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: Frequent long-term microchimerism in severe trauma patients. Blood 1999;93:3127-39.
88. Butcher EC. The regulation of lymphocyte traffic. Curr Top Microbiol Immunol 1986;128:85-122.
89. Gallatin M, St. John TP, Siegelman M, et al. Lymphocyte homing receptors. Cell 1986;44:673-80.
90. Stevenson HC, Keenan AM, Woodhouse C, et al. Fate of interferon- activated killer blood monocytes adoptively transferred into the peritoneal cavity of patients with peritoneal carcinomatosis. Cancer Res 1987;47:6100-3.
91. Mazumder A, Eberlein TJ, Grimm EA, et al. Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 1984;53:896-905.
92. Fisher B, Packard BS, Read EJ, et al. Tumor localization of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989;7:250-61.
93. AuBuchon JP Radioisotopic reflections. Transfusion 2005;45:28S-32S.
94. Vostal J. Platelet testing and evaluation guidance. Presented at the 78th meeting of the FDA Blood Products Advisory Committee. (December 13, 2003) Rockville, MD: CBER Office of Communication, Training and Manufacturers Assistance, 2003. [Available at http://www.fda. gov/ohrms/dockets/ac/03/transcripts/4014T2.htm.]
95. Piper JT, Gelderman MP, Vostal JG. In vivo recovery of human platelets in severe combined immunodeficient mice as a measure of platelet damage. Transfusion 2007;47:1540-9.
96. Dumont LJ, Dumont DF, Herschel L, et al. ATP level is superior to RBC morphology for prediction of in vivo radiolabel recoveries (abstract). Transfusion 2007;47(Suppl):32A.
97. Ross JF, Finch CA, Peacock WC, Sammons ME. The in vitro preservation and post-transfusion survival of stored blood. J Clin Invest 1947;26:687-703.
98. Dating of irradiated red blood cells. Present at the 80th meeting of the FDA Blood Products Advisory Committee. (July 22, 2004) [Available at http://www.fda.gov/ohrms/dockets/ac/04/transcripts/ 2004-4057t1.htm.]
99. Dumont LJ, AuBuchon JP for the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Evaluation of proposed FDA criteria for the evaluation of radiolabeled red cell recovery trials. Transfusion 2008;48:1053-60.
100. Hess JR, Kagen LR, van der Meer PF, et al. Interlaboratory comparison of red-cell ATP, 2,3-diphosphoglycerate and haemolysis measurements. Vox Sang 2005;89:44-8.
101. Högman CF, de Verdier CH, Ericson A, et al. Studies on the mechanism of human red cell loss of viability during storage at +4 degrees C in vitro. I. Cell shape and total adenylate concentration as determinant factors for posttransfusion survival. Vox Sang 1985;48:257-68.
102. Högman CF, De Verdier CH, Ericson A, et al. Cell shape and total adenylate concentration as important factors for posttransfusion survival of erythrocytes. Biomed Biochim Acta 1983;42:S327-31.
103. Freireich EJ, Kliman A, Gaydos LA, et al. Response to repeated platelet transfusion from the same donor. Ann Intern Med 1963;59:277-87.
104. Murphy S, Gardner FH. Room temperature storage of platelets. Transfusion 1976;16:2-3.
105. Simon TL, Nelson EJ, Carmen R, Murphy S. Extension of platelet concentrate storage. Transfusion 1983;23:207-12.
106. Kurtz SR, McMican A, Carciero R, et al. Plateletpheresis experience with the Haemonetics Blood Processor 30, the IBM Blood Processor 2997, and the Fenwal CS-3000 Blood Processor. Vox Sang 1981;41:212-8.
107. Rock G, Swenson SD, Adams GA. Platelet storage in a plasma-free medium. Transfusion 1985;25:551-6.
108. Norfolk DR, Williamson LM. Leucodepletion of blood products by filtration. Blood Rev 1995;9:7-14.
109. Pineda A, McCullough J, Benjamin RJ, for the SPRINT Study Group. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: Process used in the SPRINT trial. Transfusion 2006;46:562-71.
110. Schaller M, Hofmann A, Connor J, Nydegger UE. Filtered platelet concentrates from pooled buffy coats show comparable storage lesions when stored for 9 d at 20-24 degrees C or when supplemented with thromboSol at 2-6 degrees C. Eur J Haematol 2000;64:401-10.
111. Alving BM, Reid TJ, Fratantoni JC, Finlayson JS. Frozen platelets and platelet substitutes in transfusion medicine. Transfusion 1997;37:866-76.
112. Blajchman MA. Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemost 2003;1:1637-41.
113. Bode AP, Fischer TH. Lyophilized platelets: Fifty years in the making. Artif Cells Blood Substit Immobil Biotechnol 2007;35:125-33.
114. Fratantoni JC, Mishler JM, eds. Laboratory evaluation of platelets for transfusion. Vox Sang 1981;40(Supp 1):1-124.
115. Fratantoni JC. Comment on standardized procedures and the regulatory process. Transfusion 1986;26:36-7.
116. James V, ed. Guidelines for the blood transfusion services in the UK. 7th ed. Norwich, UK: The Stationery Office, 2005. [Available at http:// www.transfusionguidelines.org.uk/index.asp?Publication=RB.]
117. Paul-Ehrlich-Institut. Blood components for transfusion. Langen, Germany: Paul-Ehrlich-Institut, 2005. [Available at http://www.pei.de]
118. Guide to the preparation, use and quality assurance of blood components. Recommendation No. R(95) 15, 13th ed. Strasbourg: Council of Europe, 2007:151-5.
119. Kunicki TJ, Tuccelli M, Becker GA, Aster RH. A study of variables affecting the quality of platelets stored at "room temperature." Transfusion 1975;15:414-21.
120. Holme S, Moroff G, Murphy S. A multi-laboratory evaluation of in vitro platelet assays: The tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Transfusion 1998;38:31-40.
121. Rinder HM, Ault KA. Platelet activation and its detection during the preparation of platelets for transfusion. Transfus Med Rev 1998;12:271-82.
122. Murphy S, Rebulla P, Bertolini F, et al. In vitro assessment of the quality of stored platelet concentrates. Transfus Med Rev 1994;8:29-36.
123. Code of federal regulations. Title 21 CFR 640.24(d). Washington, DC: US Government Printing Office, 2007 (revised annually).
124. Food and Drug Administration. Guidance for Industry and FDA Review Staff: Collection of platelets by automated method. (December 17, 2007) Rockville, MD: CBER Office of Communication, Training, and Manufacturers Assistance, 2007.
125. Price TH, ed. Standards for blood banks and transfusion services. 25th ed. Bethesda, MD: AABB, 2008:36.
126. Commission Directive 2004/33/EC of 22 March 2004. Implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components. Official Journal of the European Union, 2004.
127. Dumont LJ, VandenBroeke T, Seven-day storage of apheresis platelets: Report of an in vitro study. Transfusion 2003;43:143-50.
128. Food and Drug Administration. Draft guidance for industry for platelet testing and evaluation of platelet substitute products. (May 20, 1999) Rockville, MD: CBER Office of Communication, Training, and Manufacturers Assistance, 1999.
129. Dumont LJ, Gulliksson H, van der Meer PF, et al. Interruption of agitation of platelet concentrates: A multicenter in vitro study by the BEST Collaborative on the effects of shipping platelets. Transfusion 2007;47:1666-73.
130. Escolar G, Garrido M, Aznar-Salatti J, et al. Comparison between human umbilical artery and rabbit abdominal aorta as substrata for platelet adhesion and platelet thrombus formation under flow conditions. Blood Vessels 1991;28:520-31.
131. Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Assessment of platelet recovery and survival by radiolabeling. Transfusion 2006;46(Suppl):43S-73S.
132. Food and Drug Administration. Safety and efficacy of methods for reducing pathogens in cellular blood products used in transfusion. (August 7-8, 2002 workshop). Rockville, MD: CBER Office of Communication, Training, and Manufacturers Assistance, 2002. [Available at: http://www.fda.gov/cber/minutes/pathtrans080802.htm.]
133. AuBuchon J, Herschel L, Roger J, Murphy S. Preliminary validation of a new standard of efficacy for stored platelets. Transfusion 2004;44:36-41.
134. AuBuchon JP, Herschel L, Roger J. Further evaluation of a new standard of efficacy for stored platelets. Transfusion 2005;45:1143-50.
135. Snyder EL, Baril L, Corda T, et al. Protocol for 51-Cr and 111-In radiolabeling of fresh blood (control) platelets in vitro (abstract). Transfusion 2004;44(Suppl):76A.
136. Slichter SJ, Harker LA. Thrombocytopenia: Mechanisms and management of defects in platelet production. Clin Haematol 1978;7:523-39.
137. Heddle NM, Cook RJ, Blajchman MA, et al. Assessing the effectiveness of whole blood-derived platelets stored as a pool: A randomized block noninferiority trial. Transfusion 2005;45:896-903.
138. Simonsen AC, Johansson PI, Conlan MG, et al. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: A pilot study. Transfusion 2006;46:424-33.
139. Manno C, Strippoli GF, Arnesano L, et al. Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. Kidney Int 2004;66:1570-7.
140. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood 2004;104:1534-41.
141. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: Making decisions about new technologies-preliminary report of a consensus conference. Vox Sang 2007;93:179-82.
142. Osselaer JC, Cazenave JP, Lambermont M, et al. An active haemo- vigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008;94:315-23.
143. Blajchman MA, Lee DH. The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. Transfus Med Rev 1997;11:95-105.
144. Hoffmeister KM, Josefsson EC, Isaac NA, et al. Glycosylation restores survival of chilled blood platelets. Science 2003;301:1531-4.
145. Valeri CR, Ragno G. The survival and function of baboon red blood cells, platelets, and plasma proteins: A review of the experience from 1972 to 2002 at the Naval Blood Research Laboratory, Boston, Massachusetts. Transfusion 2006;46(Suppl):1S-42S.
146. Button LN, Jacobson MS, Kevy SV. Rhesus monkey platelet kinetics and storage. Transfusion 1976;16:307-11.
147. Cook RJ, Heddle NM, Rebulla P, et al. for the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion 2004;44:1135-42.
148. Sandgren P, Gulliksson H, Callaert M. In vitro quality of platelet concentrates from pooled buffy-coats made of fresh and overnight stored WB processed on the novel Atreus 2c+ system (abstract). Transfusion 2007;47(Suppl):3A.
149. 51Cr. Transfusion 1992;32:113-20.
150. Dumont LJ. Analysis and reporting of platelet kinetic studies. Transfusion 2006;46:67S-73S.
151. Dumont LJ, AuBuchon JP, Whitley P, et al. Seven-day storage of single-donor platelets: Recovery and survival in an autologous transfusion study. Transfusion 2002;42:847-54.
152. Code of federal regulations. Title 21 CFR 312. Investigational New Drug Application. Washington, DC: US Government Printing Office, 2008 (revised annually).
153. Radiation dose chart. La Grange Park, IL: American Nuclear Society, 2000. [Available at http://www.ans.org/pi/resources/dose- chart (accessed February 23, 2008).]
154. Fact sheet on biological effects of radiation. Washington, DC: US Nuclear Regulatory Commission, 2007. [Available at http://www. nrc.gov/reading-rm/doc-collections/fact-sheets/bio-effects-radia- tion.html.]
155. Holmberg A, Blomstergren A, Nord O, et al. The biotin-strepta- vidin interaction can be reversibly broken using water at elevated temperatures. Electrophoresis 2005;26:501-10.
156. Strauss RG, Mock DM, Johnson K, et al. Circulating RBC volume, measured with biotinylated RBCs, is superior to the Hct to document the hematologic effects of delayed versus immediate umbilical cord clamping in preterm neonates. Transfusion 2003;43:1168-72.
157. Strauss RG, Mock DM, Widness JA, et al. Posttransfusion 24-hour recovery and subsequent survival of allogeneic red blood cells in the bloodstream of newborn infants. Transfusion 2004;44:871-6.
158. Alberio L, Dale GL. Platelet biotinylation for monitoring in vivo survival and cellular function. Platelets 1997;8:373-8.
159. Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995;23:996-1001.
160. Franco RS, Lee KN, Barker-Gear R, et al. Use of bi-level biotinylation for concurrent measurement of in vivo recovery and survival in two rabbit platelet populations. Transfusion 1994;34:784-9.
161. Rand ML, Wang H, Mody M, et al. Concurrent measurement of the survival of two populations of rabbit platelets labeled with either two PKH lipophilic dyes or two concentrations of biotin. Cytometry 2002;47:111-7.
162. Valeri CR, MacGregor H, Barnard MR, et al. Survival of baboon biotin- X-N-hydroxysuccinimide and (111)In-oxine-labeled autologous fresh and lyophilized reconstituted platelets. Vox Sang 2005;88:122-9.
163. Barnard MR, MacGregor H, Ragno G, et al. Fresh, liquid-preserved, and cryopreserved platelets: Adhesive surface receptors and membrane procoagulant activity. Transfusion 1999;39:880-8.
164. Valeri CR, Macgregor H, Giorgio A, Ragno G. Comparison of radioisotope methods and a non-radioisotope method to measure platelet survival in the baboon. Transfus Apher Sci 2005;32:275-81.
165. Stohlawetz P, Horvath M, Pernerstorfer T, et al. Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans. Transfusion 1999;39:506-14.
166. Cordle DG, Strauss RG, Lankford G, Mock DM. Antibodies provoked by the transfusion of biotin-labeled red cells. Transfusion 1999;39:1065-9.
167. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241-8.
168. Dale GI, Gaddy P, Pikul FJ. Antibodies against biotinylated proteins are present in normal human serum. J Lab Clin Med 1994;123:365-71.
169. Michelson AD, Barnard MR, Hechtman HD, et al. In vivo tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996;93:11877-82.
170. Hughes DL, Evans G, Metcalfe P, et al. Tracking and characterization of transfused platelets by two colour, whole blood flow cytometry. Br J Haematol 2005;130:791-4.